title: Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
abstract: Tumor angiogenesis plays an important role in tumor growth, aggression and metastasis. Many molecules have been demonstrated as positive regulators of angiogenesis, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and others. In recent years, significant progress has been made in the research on anti-angiogenic strategies for tumor therapies. In this review, anti-angiogenic active immunotherapies for tumors based on vaccination with xenogeneic homologous molecules and non-xenogeneic homologous molecules are discussed.
authors.affiliation: Department of Medical Microbiology and Parasitology, Zhejiang University School of Medicine, 388 Yuhangtang Road, Hangzhou, 310058, People's Republic of China. jppan@zju.edu.cn
authors.forename: Jianping
authors.initials: J
authors.lastname: Pan
authors.forename: Pengfeng
authors.initials: P
authors.lastname: Jin
authors.forename: Jie
authors.initials: J
authors.lastname: Yan
authors.forename: Dieter
authors.initials: D
authors.lastname: Kabelitz
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D019496:Cancer Vaccines; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor